In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on MAIA Biotechnology, Inc. (MAIA – Research Report), ...

MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications ...

MAIA Biotechnology's shares rose 19% to $2.46 after the company said it entered into a clinical supply agreement with BeiGene to evaluate THIO, MAIA's telomere-targeting anticancer agent.

MAIA Biotechnology (NYSE:MAIA) entered into definitive agreements for the purchase and sale of an aggregate of 507,364 shares at $1.872 per share, in a private placement to accredited investors ...

MAIA Biotechnology (MAIA) announced that it has entered into a clinical supply agreement with BeiGene (BGNE) to assess the efficacy of THIO, ...

CHICAGO, January 07, 2025--MAIA Biotechnology Announces Clinical Supply Agreement with BeiGene for Upcoming Phase 2 Trials in Three Cancer Indications CHICAGO, December 16, 2024--MAIA ...

(RTTNews) - MAIA Biotechnology (MAIA), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, on Monday, announced that the FDA has granted Rare Pediatric ...

MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that the ...

MAIA Biotechnology (NYSEAMERICAN:MAIA – Get Free Report) last released its quarterly earnings data on Tuesday, November 12th.The company reported ($0.11) earnings per share (EPS) for the quarter ...

CHICAGO, December 19, 2024--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a clinical-stage biopharmaceutical company developing ...